A small molecule-kinase interaction map for clinical kinase inhibitors

被引：1588

作者：

Fabian, MA ^{[1
]}

Biggs, WH ^{[1
]}

Treiber, DK ^{[1
]}

Atteridge, CE ^{[1
]}

Azimioara, MD ^{[1
]}

Benedetti, MG ^{[1
]}

Carter, TA ^{[1
]}

Ciceri, P ^{[1
]}

Edeen, PT ^{[1
]}

Floyd, M ^{[1
]}

Ford, JM ^{[1
]}

Galvin, M ^{[1
]}

Gerlach, JL ^{[1
]}

Grotzfeld, RM ^{[1
]}

Herrgard, S ^{[1
]}

Insko, DE ^{[1
]}

Insko, MA ^{[1
]}

Lai, AG ^{[1
]}

Lélias, JM ^{[1
]}

Mehta, SA ^{[1
]}

Milanov, ZV ^{[1
]}

Velasco, AM ^{[1
]}

Wodicka, LM ^{[1
]}

Patel, HK ^{[1
]}

Zarrinkar, PP ^{[1
]}

Lockhart, DJ ^{[1
]}

机构：

[1] Ambit Biosci, San Diego, CA 92121 USA

来源：

NATURE BIOTECHNOLOGY | 2005年 / 23卷 / 03期

关键词：

D O I：

10.1038/nbt1068

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Kinase inhibitors show great promise as a new class of therapeutics. Here we describe an efficient way to determine kinase inhibitor specificity by measuring binding of small molecules to the ATP site of kinases. We have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clinical development, against a panel of 119 protein kinases. We find that specificity varies widely and is not strongly correlated with chemical structure or the identity of the intended target. Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LICK. We also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib. Our results represent a systematic small molecule-protein interaction map for clinical compounds across a large number of related proteins.

引用

页码：329 / 336

页数：8

共 47 条

[21] p38 map kinases: Key signalling molecules as therapeutic targets for inflammatory diseases [J].

Kumar, S ;

Boehm, J ;

Lee, JC .

NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (09) :717-726

[22]

La Rosée P, 2002, CANCER RES, V62, P7149

[23] A PROTEIN-KINASE INVOLVED IN THE REGULATION OF INFLAMMATORY CYTOKINE BIOSYNTHESIS [J].

LEE, JC ;

LAYDON, JT ;

MCDONNELL, PC ;

GALLAGHER, TF ;

KUMAR, S ;

GREEN, D ;

MCNULTY, D ;

BLUMENTHAL, MJ ;

HEYS, JR ;

LANDVATTER, SW ;

STRICKLER, JE ;

MCLAUGHLIN, MM ;

SIEMENS, IR ;

FISHER, SM ;

LIVI, GP ;

WHITE, JR ;

ADAMS, JL ;

YOUNG, PR .

NATURE, 1994, 372 (6508) :739-746

[24] Novel agents in the treatment of lung cancer: Conference summary statement [J].

Lynch, TJ ;

Adjei, AA ;

Bunn, PA ;

DuBois, RN ;

Gandara, DR ;

Giaccone, G ;

Govindan, R ;

Herbst, RS ;

Johnson, BE ;

Khuri, FR ;

Perez-Soler, R ;

Rosell, R ;

Rowinsky, EK ;

Sandler, AB ;

Scagliotti, GV ;

Schiller, JH ;

Shapiro, GI ;

Socinski, MA ;

Hart, CS .

CLINICAL CANCER RESEARCH, 2004, 10 (12) :4199S-4204S

[25] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[26] The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors;: kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations [J].

Ma, YS ;

Zeng, S ;

Metcalfe, DD ;

Akin, C ;

Dimitrijevic, S ;

Butterfield, JH ;

McMahon, G ;

Longley, BJ .

BLOOD, 2002, 99 (05) :1741-1744

[27] The protein kinase complement of the human genome [J].

Manning, G ;

Whyte, DB ;

Martinez, R ;

Hunter, T ;

Sudarsanam, S .

SCIENCE, 2002, 298 (5600) :1912-+

[28]

Mattiuzzi GN, 2003, CLIN CANCER RES, V9, P976

[29] DIFFERENT SUSCEPTIBILITY OF PROTEIN-KINASES TO STAUROSPORINE INHIBITION - KINETIC-STUDIES AND MOLECULAR-BASES FOR THE RESISTANCE OF PROTEIN-KINASE CK2 [J].

MEGGIO, F ;

DEANA, AD ;

RUZZENE, M ;

BRUNATI, AM ;

CESARO, L ;

GUERRA, B ;

MEYER, T ;

METT, H ;

FABBRO, D ;

FURET, P ;

DOBROWOLSKA, G ;

PINNA, LA .

EUROPEAN JOURNAL OF BIOCHEMISTRY, 1995, 234 (01) :317-322

[30]

Moyer JD, 1997, CANCER RES, V57, P4838

← 1 2 3 4 5 →